Pilot Study Using Machine Learning to Identify Immune Profiles for the Prediction of Early Virological Relapse After Stopping Nucleos(t)ide Analogues in HBeAg-Negative CHB.
Adult
Aged
Antiviral Agents
/ therapeutic use
Biomarkers
/ blood
DNA, Viral
/ blood
Female
Guanine
/ analogs & derivatives
Hepatitis B Core Antigens
/ blood
Hepatitis B Surface Antigens
/ blood
Hepatitis B e Antigens
/ blood
Hepatitis B virus
/ drug effects
Hepatitis B, Chronic
/ blood
Humans
Interleukin-2
/ blood
Machine Learning
Male
Middle Aged
Nucleosides
/ therapeutic use
Pilot Projects
Predictive Value of Tests
Prospective Studies
Recurrence
Treatment Outcome
Withholding Treatment
Young Adult
Journal
Hepatology communications
ISSN: 2471-254X
Titre abrégé: Hepatol Commun
Pays: United States
ID NLM: 101695860
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
23
01
2020
revised:
01
09
2020
accepted:
28
09
2020
entrez:
13
1
2021
pubmed:
14
1
2021
medline:
14
1
2021
Statut:
epublish
Résumé
Treatment with nucleos(t)ide analogues (NAs) may be stopped after 1-3 years of hepatitis B virus DNA suppression in hepatitis B e antigen (HBeAg)-negative patients according to Asian Pacific Association for the Study of Liver and European Association for the Study of Liver guidelines. However, virological relapse (VR) occurs in most patients. We aimed to analyze soluble immune markers (SIMs) and use machine learning to identify SIM combinations as predictor for early VR after NA discontinuation. A validation cohort was used to verify the predictive power of the SIM combination. In a
Identifiants
pubmed: 33437904
doi: 10.1002/hep4.1626
pii: 02009842-202101000-00010
pmc: PMC7789842
doi:
Substances chimiques
Antiviral Agents
0
Biomarkers
0
DNA, Viral
0
Hepatitis B Core Antigens
0
Hepatitis B Surface Antigens
0
Hepatitis B e Antigens
0
Interleukin-2
0
Nucleosides
0
entecavir
5968Y6H45M
Guanine
5Z93L87A1R
Banques de données
ClinicalTrials.gov
['NCT02249988']
Types de publication
Clinical Trial, Phase II
Clinical Trial, Phase III
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
97-111Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2020 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of the American Association for the Study of Liver Diseases.
Références
MacLachlan JH, Locarnini S, Cowie BC. Estimating the global prevalence of hepatitis B. Lancet 2015;386:1515‐1517.
Lampertico P, Agarwal K, Berg T, Buti M, Janssen HLA, Papatheodoridis G, et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017;67:370‐398.
Cornberg M, Höner zu Siederdissen C. HBsAg seroclearance with NUCs: rare but important. Gut 2014;63:1208‐1209.
Kim G, Lim Y, An J, Lee D, Shim JH, Kim KM, et al. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut 2014;63:1325‐1332.
Zoutendijk R, Hansen BE, van Vuuren AJ, Boucher CAB, Janssen HLA. Serum HBsAg decline during long‐term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss. J Infect Dis 2011;204:415‐418.
Chevaliez S, Hézode C, Bahrami S, Grare M, Pawlotsky J. Long‐term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely. J Hepatol 2013;58:676‐683.
Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, et al. Asian‐Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012;6:531‐561.
Papatheodoridis G, Vlachogiannakos I, Cholongitas E, Wursthorn K, Thomadakis C, Touloumi G, et al. Discontinuation of oral antivirals in chronic hepatitis B: a systematic review. Hepatology 2016;63:1481‐1492.
Liem KS, Fung S, Wong DK, Yim C, Noureldin S, Chen J, et al. Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study). Gut 2019;68:2206‐2213.
Chen C, Hsu Y, Lu S, Hung C, Wang J, Lee C, et al. The incidence and predictors of HBV relapse after cessation of tenofovir therapy in chronic hepatitis B patients. J Viral Hepat 2018;25:590‐597.
Chen C, Lu S, Hung C, Wang J, Hu T, Changchien C, et al. The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment. J Hepatol 2014;61:515‐522.
Jeng W, Chen Y, Chien R, Sheen I, Liaw Y. Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen‐negative chronic hepatitis B. Hepatology 2018;68:425‐434.
Yao C, Hung C, Hu T, Lu S, Wang J, Lee C, et al. Incidence and predictors of HBV relapse after cessation of nucleoside analogues in HBeAg‐negative patients with HBsAg ≤200 IU/mL. Sci Rep 2017;7:1839.
Testoni B, Lebossé F, Scholtes C, Berby F, Miaglia C, Subic M, et al. Serum hepatitis B core‐related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. J Hepatol 2019;70:615‐625.
Höner zu Siederdissen C, Maasoumy B, Cornberg M. New viral biomarkers for hepatitis B: are we able to change practice? J Viral Hepat 2018;25:1226‐1235.
Carey I, Gersch J, Wang B, Moigboi C, Kuhns M, Cloherty G, et al. Pre‐genomic HBV RNA and HBcrAg predict outcomes in HBeAg negative chronic hepatitis B patients suppressed on nucleos(t)ide analogue therapy. Hepatology 2020;72:42‐57.
Bakker OB, Aguirre‐Gamboa R, Sanna S, Oosting M, Smeekens SP, Jaeger M, et al. Integration of multi‐omics data and deep phenotyping enables prediction of cytokine responses. Nat Immunol 2018;19:776‐786.
Yu K, Beam AL, Kohane IS. Artificial intelligence in healthcare. Nat Biomed Eng 2018;2:719‐731.
Höner zu Siederdissen C, Hui AJ, Sukeepaisarnjaroen W, Tangkijvanich P, Su WW, Nieto GEG, et al. Contrasting timing of virological relapse after discontinuation of tenofovir or entecavir in hepatitis B e antigen‐negative patients. J Infect Dis 2018;218:1480‐1484.
Jeng WJ, Chang ML, Liaw YF. Off‐therapy precipitous HBsAg decline predicts HBsAg loss after finite entecavir therapy in HBeAg‐negative patients. J Viral Hepat 2019;26:1019‐1026.
Sarin S, Kumar M, Lau G, Abbas Z, Chan H, Chen C, et al. Asian‐Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 2016;10:1‐98.
Seto W, Wong DK, Fung J, Huang F, Liu KS, Lai C, et al. Linearized hepatitis B surface antigen and hepatitis B core‐related antigen in the natural history of chronic hepatitis B. Clin Microbiol Infect 2014;20:1173‐1180.
Maasoumy B, Wiegand SB, Jaroszewicz J, Bremer B, Lehmann P, Deterding K, et al. Hepatitis B core‐related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D. Clin Microbiol Infect 2015;21:606.e1‐606.e10.
Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 2001;28:481‐504.
Pedregosa F, Varoquaux G, Gramfort A, Michel V, Thirion B, Grisel O, et al. Scikit‐learn: machine learning in python. J Machine Learn Res 2011;12:2825‐2830.
Isabelle G, André E. An introduction to variable and feature selection. J Machine Learn Res 2003;3:1157‐1182.
Gareth J, Daniela W, Trevor H, Robert T. An Introduction to Statistical Learning with Applications in R. New York, NY: Springer; 2013.
Terrault NA, Lok ASF, McMahon BJ, Chang K, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018;67:1560‐1599.
Hsu Y, Nguyen MH, Mo L, Wu M, Yang T, Chen C, et al. Combining hepatitis B core‐related and surface antigens at end of nucleos(t)ide analogue treatment to predict off‐therapy relapse risk. Aliment Pharmacol Ther 2019;49:107‐115.
Papatheodoridi M, Hadziyannis E, Berby F, Zachou K, Testoni B, Rigopoulou E, et al. Predictors of hepatitis B surface antigen loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in noncirrhotic HBeAg‐negative chronic hepatitis B. J Viral Hepat 2020;27:118‐126.
Rivino L, Le Bert N, Gill US, Kunasegaran K, Cheng Y, Tan DZ, et al. Hepatitis B virus‐specific T cells associate with viral control upon nucleos(t)ide‐analogue therapy discontinuation. J Clin Invest 2018;128:668‐681.
Wiegand SB, Beggel B, Wranke A, Aliabadi E, Jaroszewicz J, Xu C, et al. Soluble immune markers in the different phases of chronic hepatitis B virus infection. Sci Rep 2019;9:14118.
Boyman O, Sprent J. The role of interleukin‐2 during homeostasis and activation of the immune system. Nat Rev Immunol 2012;12:180‐190.
Guilhot S, Guidotti LG, Chisari FV. Interleukin‐2 downregulates hepatitis B virus gene expression in transgenic mice by a posttranscriptional mechanism. J Virol 1993;67:7444‐7449.
Groom JR, Luster AD. CXCR3 in T cell function. Exp Cell Res 2011;317:620‐631.
Bhat P, Leggatt G, Waterhouse N, Frazer IH. Interferon‐γ derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity. Cell Death Dis 2017;8:e2836.
Kakimi K, Lane TE, Chisari FV, Guidotti LG. Cutting edge: inhibition of hepatitis B virus replication by activated NK T cells does not require inflammatory cell recruitment to the liver. J Immunol 2001;167:6701‐6705.
Baumann U, Crosby HA, Ramani P, Kelly DA, Strain AJ. Expression of the stem cell factor receptor c‐kit in normal and diseased pediatric liver: identification of a human hepatic progenitor cell? Hepatology 1999;30:112‐117.
Peppa D, Gill US, Reynolds G, Easom NJW, Pallett LJ, Schurich A, et al. Up‐regulation of a death receptor renders antiviral T cells susceptible to NK cell‐mediated deletion. J Exp Med 2013;210:99‐114.
Boni C, Lampertico P, Talamona L, Giuberti T, Invernizzi F, Barili V, et al. Natural killer cell phenotype modulation and natural killer/T‐cell interplay in nucleos(t)ide analogue‐treated hepatitis e antigen‐negative patients with chronic hepatitis B. Hepatology 2015;62:1697‐1709.
Papatheodoridis GV, Rigopoulou EI, Papatheodoridi M, Zachou K, Xourafas V, Gatselis N, et al. DARING‐B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long‐term therapy before HBsAg loss in non‐cirrhotic HBeAg‐negative chronic hepatitis B. Antivir Ther (Lond) 2018;23:677‐685.
Berg T, Simon K, Mauss S, Schott E, Heyne R, Klass DM, et al. Long‐term response after stopping tenofovir disoproxil fumarate in non‐cirrhotic HBeAg‐negative patients—FINITE study. J Hepatol 2017;67:918‐924.
Ter Horst R, Jaeger M, Smeekens SP, Oosting M, Swertz MA, Li Y, et al. Host and environmental factors influencing individual human cytokine responses. Cell 2016;167:1111‐1124.e13.
Aguirre‐Gamboa R, Joosten I, Urbano PCM, van der Molen RG, van Rijssen E, van Cranenbroek B, et al. Differential effects of environmental and genetic factors on T and B cell immune traits. Cell Rep 2016;17:2474‐2487.